---
document_datetime: 2025-11-23 08:02:52
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/mabcampath.html
document_name: mabcampath.html
version: success
processing_time: 0.120828
conversion_datetime: 2025-12-28 20:10:27.934921
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# MabCampath

[RSS](/en/individual-human-medicine.xml/65511)

##### Withdrawn

This medicine's authorisation has been withdrawn

alemtuzumab

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 6 July 2001 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product MabCampath (alemtuzumab) for the treatment of patients with B-cell chronic lymphocytic leukaemia (B-CLL) for whom fludarabine combination chemotherapy is not appropriate.

The marketing authorisation holder (MAH) responsible for MabCampath was Genzyme Europe B.V. The European Commission was notified by letter of the MAH's decision to voluntarily withdraw the marketing authorisation as of the Commission Decision date for MabCampath for commercial reasons.

On 8 August 2012 the European Commission issued a decision to withdraw the marketing authorisation for MabCampath. The MAH has committed to ensure that patients who need treatment with MabCampath for B-CLL and some other transplant/oncology indications will continue to receive it through patient access programmes. Details of these programmes are being discussed at national level and will be governed by national competent authorities.

Pursuant to this decision the European Public Assessment Report for MabCampath is updated to reflect that the marketing authorisation is no longer valid.

MabCampath : EPAR - Summary for the public

English (EN) (295.96 KB - PDF)

**First published:** 05/08/2008

**Last updated:** 15/08/2012

[View](/en/documents/overview/mabcampath-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-63)

български (BG) (456.07 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/bg/documents/overview/mabcampath-epar-summary-public_bg.pdf)

español (ES) (358.05 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/es/documents/overview/mabcampath-epar-summary-public_es.pdf)

čeština (CS) (421.38 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/cs/documents/overview/mabcampath-epar-summary-public_cs.pdf)

dansk (DA) (363.26 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/da/documents/overview/mabcampath-epar-summary-public_da.pdf)

Deutsch (DE) (367.68 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/de/documents/overview/mabcampath-epar-summary-public_de.pdf)

eesti keel (ET) (359.21 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/et/documents/overview/mabcampath-epar-summary-public_et.pdf)

ελληνικά (EL) (465.91 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/el/documents/overview/mabcampath-epar-summary-public_el.pdf)

français (FR) (362.77 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/fr/documents/overview/mabcampath-epar-summary-public_fr.pdf)

italiano (IT) (362.46 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/it/documents/overview/mabcampath-epar-summary-public_it.pdf)

latviešu valoda (LV) (429.68 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/lv/documents/overview/mabcampath-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (391.94 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/lt/documents/overview/mabcampath-epar-summary-public_lt.pdf)

magyar (HU) (413.06 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/hu/documents/overview/mabcampath-epar-summary-public_hu.pdf)

Malti (MT) (360.28 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/mt/documents/overview/mabcampath-epar-summary-public_mt.pdf)

Nederlands (NL) (360.19 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/nl/documents/overview/mabcampath-epar-summary-public_nl.pdf)

polski (PL) (422.26 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/pl/documents/overview/mabcampath-epar-summary-public_pl.pdf)

português (PT) (358.86 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/pt/documents/overview/mabcampath-epar-summary-public_pt.pdf)

română (RO) (390.46 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/ro/documents/overview/mabcampath-epar-summary-public_ro.pdf)

slovenčina (SK) (418.05 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/sk/documents/overview/mabcampath-epar-summary-public_sk.pdf)

slovenščina (SL) (414.53 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/sl/documents/overview/mabcampath-epar-summary-public_sl.pdf)

Suomi (FI) (362.01 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/fi/documents/overview/mabcampath-epar-summary-public_fi.pdf)

svenska (SV) (360.2 KB - PDF)

**First published:**

05/08/2008

**Last updated:**

15/08/2012

[View](/sv/documents/overview/mabcampath-epar-summary-public_sv.pdf)

## Product information

MabCampath : EPAR - Product Information

English (EN) (719.68 KB - PDF)

**First published:** 03/08/2009

**Last updated:** 15/08/2012

[View](/en/documents/product-information/mabcampath-epar-product-information_en.pdf)

[Other languages (23)](#file-language-dropdown-867)

български (BG) (2.32 MB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/bg/documents/product-information/mabcampath-epar-product-information_bg.pdf)

español (ES) (754.94 KB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/es/documents/product-information/mabcampath-epar-product-information_es.pdf)

čeština (CS) (1.33 MB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/cs/documents/product-information/mabcampath-epar-product-information_cs.pdf)

dansk (DA) (757.61 KB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/da/documents/product-information/mabcampath-epar-product-information_da.pdf)

Deutsch (DE) (794.63 KB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/de/documents/product-information/mabcampath-epar-product-information_de.pdf)

eesti keel (ET) (718.2 KB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/et/documents/product-information/mabcampath-epar-product-information_et.pdf)

ελληνικά (EL) (2.13 MB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/el/documents/product-information/mabcampath-epar-product-information_el.pdf)

français (FR) (779 KB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/fr/documents/product-information/mabcampath-epar-product-information_fr.pdf)

íslenska (IS) (763.38 KB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/is/documents/product-information/mabcampath-epar-product-information_is.pdf)

italiano (IT) (923.7 KB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/it/documents/product-information/mabcampath-epar-product-information_it.pdf)

latviešu valoda (LV) (1.52 MB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/lv/documents/product-information/mabcampath-epar-product-information_lv.pdf)

lietuvių kalba (LT) (924.51 KB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/lt/documents/product-information/mabcampath-epar-product-information_lt.pdf)

magyar (HU) (1.52 MB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/hu/documents/product-information/mabcampath-epar-product-information_hu.pdf)

Malti (MT) (1.48 MB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/mt/documents/product-information/mabcampath-epar-product-information_mt.pdf)

Nederlands (NL) (781.97 KB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/nl/documents/product-information/mabcampath-epar-product-information_nl.pdf)

norsk (NO) (772.05 KB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/no/documents/product-information/mabcampath-epar-product-information_no.pdf)

polski (PL) (1.53 MB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/pl/documents/product-information/mabcampath-epar-product-information_pl.pdf)

português (PT) (808.18 KB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/pt/documents/product-information/mabcampath-epar-product-information_pt.pdf)

română (RO) (1.12 MB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/ro/documents/product-information/mabcampath-epar-product-information_ro.pdf)

slovenčina (SK) (1.41 MB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/sk/documents/product-information/mabcampath-epar-product-information_sk.pdf)

slovenščina (SL) (1.33 MB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/sl/documents/product-information/mabcampath-epar-product-information_sl.pdf)

Suomi (FI) (731.81 KB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/fi/documents/product-information/mabcampath-epar-product-information_fi.pdf)

svenska (SV) (764.74 KB - PDF)

**First published:**

03/08/2009

**Last updated:**

15/08/2012

[View](/sv/documents/product-information/mabcampath-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0055 06/07/2001

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

MabCampath : EPAR - All Authorised presentations

English (EN) (272.14 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 15/08/2012

[View](/en/documents/all-authorised-presentations/mabcampath-epar-all-authorised-presentations_en.pdf)

[Other languages (18)](#file-language-dropdown-832)

español (ES) (272.05 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/08/2012

[View](/es/documents/all-authorised-presentations/mabcampath-epar-all-authorised-presentations_es.pdf)

čeština (CS) (306 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/08/2012

[View](/cs/documents/all-authorised-presentations/mabcampath-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (275.76 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/08/2012

[View](/da/documents/all-authorised-presentations/mabcampath-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (277.64 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/08/2012

[View](/de/documents/all-authorised-presentations/mabcampath-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (271.14 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/08/2012

[View](/et/documents/all-authorised-presentations/mabcampath-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (305.48 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/08/2012

[View](/el/documents/all-authorised-presentations/mabcampath-epar-all-authorised-presentations_el.pdf)

français (FR) (271.55 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/08/2012

[View](/fr/documents/all-authorised-presentations/mabcampath-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (270.37 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/08/2012

[View](/it/documents/all-authorised-presentations/mabcampath-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (306.2 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/08/2012

[View](/lv/documents/all-authorised-presentations/mabcampath-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (292.81 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/08/2012

[View](/lt/documents/all-authorised-presentations/mabcampath-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (282.5 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/08/2012

[View](/hu/documents/all-authorised-presentations/mabcampath-epar-all-authorised-presentations_hu.pdf)

Nederlands (NL) (272.48 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/08/2012

[View](/nl/documents/all-authorised-presentations/mabcampath-epar-all-authorised-presentations_nl.pdf)

polski (PL) (308.4 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/08/2012

[View](/pl/documents/all-authorised-presentations/mabcampath-epar-all-authorised-presentations_pl.pdf)

português (PT) (272.35 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/08/2012

[View](/pt/documents/all-authorised-presentations/mabcampath-epar-all-authorised-presentations_pt.pdf)

slovenčina (SK) (294.55 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/08/2012

[View](/sk/documents/all-authorised-presentations/mabcampath-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (282.36 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/08/2012

[View](/sl/documents/all-authorised-presentations/mabcampath-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (270.21 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/08/2012

[View](/fi/documents/all-authorised-presentations/mabcampath-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (274.52 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/08/2012

[View](/sv/documents/all-authorised-presentations/mabcampath-epar-all-authorised-presentations_sv.pdf)

MabCampath : EPAR - Conditions imposed on member states for safe and effective use - Annex IV

English (EN) (245.34 KB - PDF)

**First published:** 07/02/2008

**Last updated:** 16/08/2012

[View](/en/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_en.pdf)

[Other languages (21)](#file-language-dropdown-979)

български (BG) (351.45 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/bg/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_bg.pdf)

español (ES) (246.13 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/es/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_es.pdf)

čeština (CS) (339.66 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/cs/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_cs.pdf)

dansk (DA) (257.71 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/da/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_da.pdf)

Deutsch (DE) (246.27 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/de/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_de.pdf)

eesti keel (ET) (243.51 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/et/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_et.pdf)

ελληνικά (EL) (349.2 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/el/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_el.pdf)

français (FR) (247.25 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/fr/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fr.pdf)

italiano (IT) (245.44 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/it/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_it.pdf)

latviešu valoda (LV) (342.88 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/lv/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lv.pdf)

lietuvių kalba (LT) (322.26 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/lt/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lt.pdf)

magyar (HU) (334.51 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/hu/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_hu.pdf)

Malti (MT) (341.79 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/mt/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_mt.pdf)

Nederlands (NL) (246.19 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/nl/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_nl.pdf)

polski (PL) (345.78 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/pl/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pl.pdf)

português (PT) (245.88 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/pt/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pt.pdf)

română (RO) (321.03 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/ro/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_ro.pdf)

slovenčina (SK) (340.27 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/sk/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sk.pdf)

slovenščina (SL) (333.35 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/sl/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sl.pdf)

Suomi (FI) (245.72 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/fi/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fi.pdf)

svenska (SV) (245.78 KB - PDF)

**First published:**

07/02/2008

**Last updated:**

16/08/2012

[View](/sv/documents/conditions-member-states/mabcampath-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sv.pdf)

## Product details

Name of medicine MabCampath Active substance alemtuzumab International non-proprietary name (INN) or common name alemtuzumab Therapeutic area (MeSH) Leukemia, Lymphocytic, Chronic, B-Cell Anatomical therapeutic chemical (ATC) code L01XC04

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

MabCampath is indicated for the treatment of patients with B-cell chronic lymphocytic leukaemia (BCLL) for whom fludarabine combination chemotherapy is not appropriate.

## Authorisation details

EMA product number EMEA/H/C/000353 Marketing authorisation holder

Genzyme Europe B.V.

Paasheuvelweg 25

Marketing authorisation issued 06/07/2001 Withdrawal of marketing authorisation 08/08/2012 Revision 14

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

MabCampath : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (352.76 KB - PDF)

**First published:** 03/08/2009

**Last updated:** 15/08/2012

[View](/en/documents/procedural-steps-after/mabcampath-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

MabCampath-H-C-353-II-30 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (861.51 KB - PDF)

**First published:** 07/02/2008

**Last updated:** 16/08/2012

[View](/en/documents/scientific-discussion-variation/mabcampath-h-c-353-ii-30-epar-scientific-discussion-variation_en.pdf)

MabCampath : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (301.18 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 15/08/2012

[View](/en/documents/steps-after-cutoff/mabcampath-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

MabCampath : EPAR - Scientific Discussion

English (EN) (620.02 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 15/08/2012

[View](/en/documents/scientific-discussion/mabcampath-epar-scientific-discussion_en.pdf)

MabCampath : EPAR - Procedural steps taken before authorisation

English (EN) (302.77 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 15/08/2012

[View](/en/documents/procedural-steps/mabcampath-epar-procedural-steps-taken-authorisation_en.pdf)

**This page was last updated on** 15/08/2012

## Share this page

[Back to top](#main-content)